REGENXBIO INC. DL-,0001 WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0 Forum: Aktien Thema: Hauptdiskussion

REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy https://www.prnewswire.com/news-releases/regenxbio-announces-update-on-rgx-314-and-pivotal-program-for-the-treatment-of-wet-amd-and-new-gene-therapy-program-for-the-treatment-of-duchenne-muscular-dystrophy-301201378.html

REGENXBIO Announces Agreement to Monetize Portion of Zolgensma Royalties for $200 Million https://www.prnewswire.com/news-releases/regenxbio-announces-agreement-to-monetize-portion-of-zolgensma-royalties-for-200-million-301197818.html Agreement with Healthcare Royalty enables REGENXBIO to advance its broad gene therapy pipeline, including pivotal program for RGX-314 ...

Regenxbio: Championing Gene Therapy https://seekingalpha.com/article/4395464-regenxbio-championing-gene-therapy

https://www.prnewswire.com/news-releases/regenxbio-announces-dosing-of-first-patient-in-phase-ii-altitude-trial-of-rgx-314-for-the-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery-301190019.html

REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II https://www.prnewswire.com/news-releases/regenxbio-announces-positive-interim-data-and-update-for-phase-iii-trial-of-rgx-121-for-the-treatment-of-mps-ii-301189001.html - Consistent reductions in CSF levels of heparan sulfate up to 2 years after administration, as well as continued developmental skill acquisition - Initial data from Cohort 2 indicates evidence of systemic enzyme expression and biomarker activity - Additional data from Cohorts 1 and 2 to be presented at WORLDSymposium in February 2021 - REGENXBIO expects to initiate dosing of patients in Cohort 3 at an increased dose in the first quarter of 2021 ...

Regenxbio EPS beats by $1.14, beats on revenue https://seekingalpha.com/news/3631476-regenxbio-eps-beats-1_14-beats-on-revenue Regenxbio (NASDAQ:RGNX): Q3 GAAP EPS of $0.24 beats by $1.14. Revenue of $98.9M (+572.8% Y/Y) beats by $74.1M.

REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II) https://www.prnewswire.com/news-releases/regenxbio-announces-continued-progress-and-expansion-of-clinical-development-program-for-rgx-121-for-the-treatment-of-mucopolysaccharidosis-type-ii-mps-ii-301141550.html

https://dc.citybizlist.com/article/628211/regenxbio-more-robust-data-for-wet-amd Regenxbio: More Robust Data For Wet AMD

https://seekingalpha.com/article/4373916-regenxbio-robust-data-for-wet-amd

https://www.prnewswire.com/news-releases/regenxbio-announces-dosing-of-first-patient-in-phase-ii-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery-301126029.html

Regenxbio EPS misses by $0.06, misses on revenue https://seekingalpha.com/news/3602262-regenxbio-eps-misses-0_06-misses-on-revenue

Regenxbio (RGNX) Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD https://www.streetinsider.com/dr/news.php?id=17190831&gfv=1

https://pub.webull.com/us/news-html/81ce1297530341788bf4e973b7c5b77d.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en&theme=1

REGENXBIO (RGNX) Investor Presentation - Slideshow https://seekingalpha.com/article/4354375

Regenxbio EPS misses by $0.22, misses on revenue https://seekingalpha.com/news/3571576

https://www.pharmiweb.com/press-release/2020-05-07/regenxbio-reports-first-quarter-2020-financial-results-and-operational-highlights REGENXBIO berichtet über die Finanzergebnisse und operativen Highlights des ersten Quartals 2020